Literature DB >> 19269363

Principles of cancer therapy: oncogene and non-oncogene addiction.

Ji Luo1, Nicole L Solimini, Stephen J Elledge.   

Abstract

Cancer is a complex collection of distinct genetic diseases united by common hallmarks. Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis. We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells. In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets. Finally, we discuss the path ahead to therapeutic discovery and provide theoretical considerations for combining orthogonal cancer therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19269363      PMCID: PMC2894612          DOI: 10.1016/j.cell.2009.02.024

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  124 in total

1.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 2.  Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

Authors:  G Selivanova; K G Wiman
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

3.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

Review 4.  Targeting TRAIL agonistic receptors for cancer therapy.

Authors:  Carmelo Carlo-Stella; Cristiana Lavazza; Alberta Locatelli; Lucia Viganò; Alessandro M Gianni; Luca Gianni
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

Review 5.  Tetraploidy, aneuploidy and cancer.

Authors:  Neil J Ganem; Zuzana Storchova; David Pellman
Journal:  Curr Opin Genet Dev       Date:  2007-02-26       Impact factor: 5.578

6.  Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map.

Authors:  Sean R Collins; Kyle M Miller; Nancy L Maas; Assen Roguev; Jeffrey Fillingham; Clement S Chu; Maya Schuldiner; Marinella Gebbia; Judith Recht; Michael Shales; Huiming Ding; Hong Xu; Junhong Han; Kristin Ingvarsdottir; Benjamin Cheng; Brenda Andrews; Charles Boone; Shelley L Berger; Phil Hieter; Zhiguo Zhang; Grant W Brown; C James Ingles; Andrew Emili; C David Allis; David P Toczyski; Jonathan S Weissman; Jack F Greenblatt; Nevan J Krogan
Journal:  Nature       Date:  2007-02-21       Impact factor: 49.962

Review 7.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 8.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 9.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

10.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

View more
  794 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.

Authors:  Yun-Chi Tang; Hui Yuwen; Kaiying Wang; Peter M Bruno; Kevin Bullock; Amy Deik; Stefano Santaguida; Marianna Trakala; Sarah J Pfau; Na Zhong; Tao Huang; Lan Wang; Clary B Clish; Michael T Hemann; Angelika Amon
Journal:  Cancer Res       Date:  2017-08-03       Impact factor: 12.701

3.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Authors:  David Y Chen; Yishan Lee; Brian A Van Tine; Adam C Searleman; Todd D Westergard; Han Liu; Ho-Chou Tu; Shugaku Takeda; Yiyu Dong; David R Piwnica-Worms; Kyoung J Oh; Stanley J Korsmeyer; Ann Hermone; Richard Gussio; Robert H Shoemaker; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2011-12-13       Impact factor: 12.701

4.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

5.  RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis.

Authors:  Anthony J Saporita; Hsiang-Chun Chang; Crystal L Winkeler; Anthony J Apicelli; Raleigh D Kladney; Jianbo Wang; R Reid Townsend; Loren S Michel; Jason D Weber
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 6.  The Multifaceted Role of HSF1 in Tumorigenesis.

Authors:  Milad J Alasady; Marc L Mendillo
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Authors:  Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

8.  Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies.

Authors:  Elizabeth J Pereira; Joseph S Burns; Christina Y Lee; Taylor Marohl; Delia Calderon; Lixin Wang; Kristen A Atkins; Chun-Chao Wang; Kevin A Janes
Journal:  Sci Signal       Date:  2020-04-14       Impact factor: 8.192

9.  Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.

Authors:  Antonina Mitrofanova; Alvaro Aytes; Min Zou; Michael M Shen; Cory Abate-Shen; Andrea Califano
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

10.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.